The stock of Relay Therapeutics Inc (RLAY) has gone up by 4.88% for the week, with a -12.37% drop in the past month and a -28.00% drop in the past quarter. The volatility ratio for the week is 6.83%, and the volatility levels for the past 30 days are 6.30% for RLAY. The simple moving average for the past 20 days is 0.72% for RLAY’s stock, with a -27.68% simple moving average for the past 200 days.
Is It Worth Investing in Relay Therapeutics Inc (NASDAQ: RLAY) Right Now?
Additionally, the 36-month beta value for RLAY is 1.68. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for RLAY is 93.02M and currently, short sellers hold a 11.49% ratio of that float. The average trading volume of RLAY on May 02, 2024 was 1.22M shares.
RLAY) stock’s latest price update
Relay Therapeutics Inc (NASDAQ: RLAY)’s stock price has soared by 2.15 in relation to previous closing price of 6.52. Nevertheless, the company has seen a gain of 4.88% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-25 that CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Thursday, May 2, 2024.
Analysts’ Opinion of RLAY
Many brokerage firms have already submitted their reports for RLAY stocks, with Jefferies repeating the rating for RLAY by listing it as a “Hold.” The predicted price for RLAY in the upcoming period, according to Jefferies is $12.50 based on the research report published on April 20, 2023 of the previous year 2023.
Raymond James, on the other hand, stated in their research note that they expect to see RLAY reach a price target of $29. The rating they have provided for RLAY stocks is “Strong Buy” according to the report published on April 19th, 2023.
Raymond James gave a rating of “Outperform” to RLAY, setting the target price at $29 in the report published on April 13th of the previous year.
RLAY Trading at -17.95% from the 50-Day Moving Average
After a stumble in the market that brought RLAY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.00% of loss for the given period.
Volatility was left at 6.30%, however, over the last 30 days, the volatility rate increased by 6.83%, as shares sank -6.72% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -37.82% lower at present.
During the last 5 trading sessions, RLAY rose by +4.88%, which changed the moving average for the period of 200-days by -48.37% in comparison to the 20-day moving average, which settled at $6.59. In addition, Relay Therapeutics Inc saw -39.51% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RLAY starting from Bergstrom Donald A, who sale 2,686 shares at the price of $6.38 back on Apr 29 ’24. After this action, Bergstrom Donald A now owns 527,427 shares of Relay Therapeutics Inc, valued at $17,137 using the latest closing price.
Catinazzo Thomas, the Chief Financial Officer of Relay Therapeutics Inc, sale 1,695 shares at $6.38 during a trade that took place back on Apr 29 ’24, which means that Catinazzo Thomas is holding 339,803 shares at $10,814 based on the most recent closing price.
Stock Fundamentals for RLAY
Current profitability levels for the company are sitting at:
- -14.6 for the present operating margin
- 0.79 for the gross margin
The net margin for Relay Therapeutics Inc stands at -13.11. The total capital return value is set at -0.46. Equity return is now at value -40.18, with -35.19 for asset returns.
Based on Relay Therapeutics Inc (RLAY), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -5.62.
Currently, EBITDA for the company is -380.57 million with net debt to EBITDA at 0.24. When we switch over and look at the enterprise to sales, we see a ratio of 30.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 25.44.
Conclusion
In conclusion, Relay Therapeutics Inc (RLAY) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
